Prot# RV-LYM-PI-017: Phase II Trial of CC-5013 (Revlimid?) in Patients with Cutaneous T-Cell Lymphoma (NU Prot# NU 04H5)

Project: Research project

Project Details

StatusFinished
Effective start/end date1/28/0510/31/17

Funding

  • Celgene Corporation (RV-LYM-PI-017)